{"entity":{"id":"nct04182516","kind":"trial","name":"Study of NMS-03305293 in Pts with Selected Advanced/Metastatic Solid Tumors","aka":[],"tldr":"This study tests a PARP inhibitor; the registry reports that it is terminated.","summary":"The registry lists NCT04182516 as terminated, last updated 2024-09-19. Enrolment is 52 actual participants. Interventions: NMS-03305293. Primary measures include Number of Participants with first-cycle dose limiting toxicity. The registry reason for stopping is: The study closure is related to sponsor decision to shift towards the clinical development of NMS-03305293 in combination in a broader range of indication and not based on emerging safety or efficacy concerns. No results are posted in the registry; this does not exclude separate publications.","status":"withdrawn","asOf":"2026-10-06","links":[{"label":"ClinicalTrials.gov NCT04182516","url":"https://clinicaltrials.gov/study/NCT04182516"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":["parp"],"drugs":["nms-03305293"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT04182516","phase":"1","setting":"A Phase I Dose Escalation Study of NMS-03305293 in Adult Patients with Selected Advanced/Metastatic Solid Tumors","sponsor":"Nerviano Medical Sciences","started":"2019-11-25","startedType":"actual","enrolled":52,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct04182516/","neighbours":{"target":[{"id":"parp","kind":"target","name":"PARP","route":"/targets/parp/"}],"drug":[{"id":"nms-03305293","kind":"drug","name":"NMS-03305293","route":"/drugs/nms-03305293/"}]}}